Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05460169 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Renal Denervation in ADPKD- RDN-ADPKD Study

Study acronym: RDN-ADPKD
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv6
  2. Primary completion date: Feb 2027 to Mar 2028
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: May 2027 to Mar 2028
    • Site details revised
    v5
  3. Secondary endpoints: 19 to 32v4
  4. Primary completion date: Feb 2026 to Feb 2027
    • Study completion date: May 2026 to May 2027
    • Secondary endpoints: details revised at 17 of 19 entries
    • Study description shortened, about 10 words
    v3
  5. Primary completion date: Jan 2024 to Feb 2026v2 Show 5 more changesShow less
    • Enrollment target: 40 to 44
    • Study completion date: Nov 2024 to May 2026
    • Eligibility criteria revised
    • Secondary endpoints: 20 to 19
    • Study description expanded, about 30 words
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RDN-ADPKD is a prospective, randomized (1:1, central randomization), single-center, hypothesis-generating, feasibility study. The purpose of the RDN-ADPKD study is to demonstrate efficacy and document safety of renal denervation (RDN) with the Paradise System in hypertensive patients with ADPKD.
Trial Details
NCT Number NCT05460169
Lead Sponsor University of Erlangen-Nürnberg Medical School
Conditions
(from sponsor)		 Uncontrolled Hypertension, Autosomal Dominant Polycystic Kidney Disease, Renal Denervation
Related terms Polycystic Kidney, Autosomal Dominant
Enrollment 44 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov